Time-series characterisation of cholera outbreaks and optimisation of oral cholera vaccine resource allocation in Africa, 2010–2023
Full Text

Keywords

Cholera
Surveillance
Time series
Seasonality
Oral cholera vaccine
Transmission modelling
Cost-effectiveness
Resource allocation
Africa

Categories

How to Cite

Idris Mustapha, A., Oluwaseun Adebayo Ogundijo, Fatoumata Bintou Sarr, Tsehaynesh Meseret Desta, & Chola Mulenga Mwansa. (2026). Time-series characterisation of cholera outbreaks and optimisation of oral cholera vaccine resource allocation in Africa, 2010–2023. Journal of Public Health and Preventive Medicine, 2(9), 37-45. https://doi.org/10.64904/20260905
Crossmark

Abstract

Background: Cholera remains a major cause of epidemic disease in Africa, and the Global Task Force on Cholera Control (GTFCC) roadmap targets a 90% reduction in cholera mortality by 2030 through improved water and sanitation, surveillance and targeted oral cholera vaccine (OCV) use. Optimal allocation of a limited global OCV stock across countries with different transmission dynamics is a central operational question, yet quantitative, surveillance-based guidance is scarce. Methods: Using the Johns Hopkins Global Cholera Monitoring Database — a harmonised, location-masked, country-level weekly time series of suspected and confirmed cases and deaths for 34 African countries, 2010–2023 (1·004·144 reported suspected cases) — we characterised national transmission patterns by k-means clustering of incidence, seasonality and persistence features, with hierarchical clustering for cross-validation. We then calibrated a susceptible–infected–recovered–environment (SIRB) transmission model with seasonal forcing and importation to each pattern, and simulated preventive, reactive and mixed OCV strategies (10–50% coverage; vaccine effectiveness 75%). We computed cost-effectiveness (USD per DALY averted; CFR 2%; $2 per dose) and optimised cross-pattern dose allocation by greedy marginal benefit. Results: Three reproducible transmission patterns were identified: persistent-endemic (3 countries; 43·4% of cases), rainy-season-driven (18 countries; 55·4%) and sporadic-imported (10 countries; 1·2%). Preventive annual campaigns (25% coverage) averted 89·1% of cases in persistent-endemic and 77·3% in rainy-season-driven settings, exceeding reactive campaigns (85·5% and 60·6%) at equal coverage; in sporadic-imported settings, even 50% reactive coverage averted only 33·0% of cases. Across full-Africa strategies, ICERs ranged from $9·27/DALY (preventive 10%) to $14·67/DALY (targeted preventive), all far below a $1·600/DALY willingness-to-pay threshold and robust to sensitivity analyses (ICER range $4·7–$51·4/DALY). Greedy allocation concentrated doses in rainy-season-driven and persistent-endemic patterns, sparing sporadic-imported settings, and averted 49·7% more cases than equal per-pattern allocation at the same budget. Conclusion: Transmission-pattern-aware OCV programming — preventive campaigns timed to seasonal peaks in endemic and seasonally driven settings, with reactive response reserved for sporadic importation hotspots — could substantially improve the efficiency of the global cholera stockpile and accelerate progress towards the GTFCC 2030 goals.

Full Text

References

[1] Zheng, Q., DePencier, R., Demby, M. N., Azman, A. S., & Lee, E. C. (2026). Cholera surveillance time series in Africa between 2010 and 2023. Gates Open Research, 10, 16. https://doi.org/10.12688/gatesopenres.16378.1

[2] Reyburn, R., Kim, D. R., Emch, M., Khatib, A., von Seidlein, L., & Ali, M. (2011). Climate variability and the outbreaks of cholera in Zanzibar, East Africa: A time series analysis. The American Journal of Tropical Medicine and Hygiene, 84(6), 862–869. https://doi.org/10.4269/ajtmh.2011.10-0277

[3] Schwerdtle, P., Onekon, C. K., & Recoche, K. (2018). A quantitative systematic review and meta-analysis of the effectiveness of oral cholera vaccine as a reactive measure in cholera outbreaks. Prehospital and Disaster Medicine, 33(1), 2–6. https://doi.org/10.1017/S1049023X17007166

[4] Azman, A. S., & Lessler, J. (2015). Reactive vaccination in the presence of disease hotspots. Proceedings of the Royal Society B: Biological Sciences, 282(1798), 20141341. https://doi.org/10.1098/rspb.2014.1341

[5] Ilboudo, P. G., Mengel, M. A., Gessner, B. D., Ngwira, B., Cavailler, P., & Le Gargasson, J. B. (2021). Cost-effectiveness of a reactive oral cholera immunization campaign using Shanchol in Malawi. Cost Effectiveness and Resource Allocation, 19(1), 17. https://doi.org/10.1186/s12962-021-00270-y

[6] Mogasale, V., Ngogoyo, S. M., & Mogasale, V. V. (2021). Model-based estimation of the economic burden of cholera in Africa. BMJ Open, 11(3), e044615. https://doi.org/10.1136/bmjopen-2020-044615

[7] Legros, D., & Partners of the Global Task Force on Cholera Control. (2018). Global cholera epidemiology: Opportunities to reduce the burden of cholera by 2030. The Journal of Infectious Diseases, 218(Suppl_3), S137–S140. https://doi.org/10.1093/infdis/jiy486

[8] World Health Organization. (2017). Cholera vaccines: WHO position paper – August 2017. Weekly Epidemiological Record, 92(34), 477–498.

[9] Bateyi Mustafa, S. H., Patrick, T., Raoul, R. Z., & Dominique, B. B. (2026). Oral cholera vaccines as transmission-interrupting tools for cholera control: A narrative review. Infection and Drug Resistance, 19, 626896. https://doi.org/10.2147/IDR.S626896

[10] World Health Organization. (2018). Cholera vaccine: WHO position paper, August 2017 – Recommendations. Vaccine, 36(24), 3418–3420. https://doi.org/10.1016/j.vaccine.2017.09.034

[11] Anteneh, L. M., Lokonon, B. E., & Kakaï, R. G. (2024). Modelling techniques in cholera epidemiology: A systematic and critical review. Mathematical Biosciences, 373, 109210. https://doi.org/10.1016/j.mbs.2024.109210

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2026 Journal of Public Health and Preventive Medicine